• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国商业保险儿童侵袭性肺炎球菌疾病、全因性肺炎和全因性中耳炎的成本。

Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children.

作者信息

Averin Ahuva, Weycker Derek, Lapidot Rotem, Rozenbaum Mark H, Huang Liping, Vietri Jeffrey, Arguedas Mohs Adriano, Cane Alejandro, Lonshteyn Alexander, Pelton Stephen I

机构信息

Avalere Health, Boston, Massachusetts, USA.

Boston Medical Center, Boston, Massachusetts, USA.

出版信息

J Med Econ. 2025 Dec;28(1):517-523. doi: 10.1080/13696998.2025.2484919. Epub 2025 Apr 3.

DOI:10.1080/13696998.2025.2484919
PMID:40152182
Abstract

BACKGROUND

Invasive pneumococcal disease (IPD), pneumonia (PNE), and otitis media (OM) are significant causes of morbidity among children in the United States (US). While studies have evaluated the economic burden of these conditions, recent data on episodic costs of IPD, PNE, and OM requiring hospitalization or ambulatory care only among US children by age and comorbidity profile are currently not available. This study was undertaken to address this evidence gap.

METHODS

A retrospective observational cohort design and data (2015-2019) from Optum's de-identified Clinformatics Data Mart Database were employed. Episodes of IPD, all-cause PNE, and all-cause OM were ascertained on a monthly basis during the follow-up period and stratified by care setting (hospital vs. ambulatory); all-cause OM was alternatively stratified by disease severity (acute, persistent, tympanostomy tube placement) and, for acute/persistent, by complexity (simple, complex). Mean episodic costs of disease were estimated for children aged <1, 1-<2, 2-<6, and 6-<18 years, respectively, overall and by comorbidity profile (with vs. without ≥1 medical condition).

RESULTS

Mean age-specific cost of IPD hospitalization ranged from $40,575-$95,607; IPD requiring care in an emergency department (ED), from $2,013-$5,606; and IPD requiring care in other ambulatory settings, from $619-$1,103. Mean cost of all-cause PNE ranged from $16,631-$21,429 for hospitalized cases; $2,462-$2,685 for ED cases; and $424-$473 for other ambulatory cases. Corresponding ranges for all-cause OM were $14,599-$16,341; $1,190-$2,083; and $253-$514. Children with (vs. without) comorbidities had higher mean costs of PNE episodes across all ages and care settings; mean cost of all-cause OM was largely invariant by comorbidity profile and was highest for episodes involving TTP.

CONCLUSIONS

Costs of IPD, all-cause PNE, and all-cause OM are high, particularly in the hospital setting. All-cause PNE, one of the most common causes of hospitalization for children, is particularly costly for children with comorbidities.

摘要

背景

侵袭性肺炎球菌疾病(IPD)、肺炎(PNE)和中耳炎(OM)是美国儿童发病的重要原因。虽然已有研究评估了这些疾病的经济负担,但目前尚无关于美国儿童中仅需住院治疗或门诊治疗的IPD、PNE和OM按年龄和合并症情况划分的单次发作成本的最新数据。本研究旨在填补这一证据空白。

方法

采用回顾性观察队列设计,并使用了Optum公司去识别化的临床信息数据集市数据库中的数据(2015 - 2019年)。在随访期间每月确定IPD、全因性PNE和全因性OM的发作情况,并按护理环境(住院与门诊)进行分层;全因性OM也可按疾病严重程度(急性、持续性、鼓膜置管)分层,对于急性/持续性OM,还可按复杂性(简单、复杂)分层。分别估算了年龄小于1岁、1 - 2岁、2 - 6岁和6 - 18岁儿童疾病的平均单次发作成本,总体情况以及按合并症情况(有≥1种疾病与无疾病)进行估算。

结果

IPD住院的特定年龄平均成本在40,575美元至95,607美元之间;在急诊科(ED)接受治疗的IPD,成本在2,013美元至5,606美元之间;在其他门诊环境接受治疗的IPD,成本在619美元至1,103美元之间。全因性PNE住院病例的平均成本在16,631美元至21,429美元之间;急诊科病例的成本在2,462美元至2,685美元之间;其他门诊病例的成本在424美元至473美元之间。全因性OM的相应成本范围分别为14,599美元至16,341美元;1,190美元至2,083美元;253美元至514美元。患有合并症(与无合并症相比)的儿童在所有年龄和护理环境下PNE发作的平均成本更高;全因性OM的平均成本在很大程度上不受合并症情况的影响,且涉及鼓膜置管的发作成本最高。

结论

IPD、全因性PNE和全因性OM的成本很高,尤其是在医院环境中。全因性PNE是儿童住院的最常见原因之一,对于患有合并症的儿童来说成本尤其高昂。

相似文献

1
Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children.美国商业保险儿童侵袭性肺炎球菌疾病、全因性肺炎和全因性中耳炎的成本。
J Med Econ. 2025 Dec;28(1):517-523. doi: 10.1080/13696998.2025.2484919. Epub 2025 Apr 3.
2
Burden of invasive pneumococcal disease, non-invasive all-cause pneumonia, and acute otitis media in hospitalized US children: a retrospective multi-center study from 2015 to 2020.美国住院儿童侵袭性肺炎球菌疾病、非侵袭性全因性肺炎和急性中耳炎的负担:一项2015年至2020年的回顾性多中心研究。
BMC Health Serv Res. 2024 Dec 18;24(1):1574. doi: 10.1186/s12913-024-11898-w.
3
Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018.2014-2018 年在美国使用 13 价肺炎球菌结合疫苗后,儿童急性中耳炎、肺炎和侵袭性肺炎球菌病的经济负担。
BMC Health Serv Res. 2023 Apr 25;23(1):398. doi: 10.1186/s12913-023-09244-7.
4
Clinical and economic burden of otitis media in children under 5 years of age in the United States: A retrospective study.美国 5 岁以下儿童中耳炎的临床和经济负担:一项回顾性研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2409510. doi: 10.1080/21645515.2024.2409510. Epub 2024 Oct 18.
5
A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015.一项基于人群的研究,旨在探讨2015年13价肺炎球菌结合疫苗纳入儿童免疫规划前后台湾地区住院儿童肺炎球菌疾病的负担。
BMC Infect Dis. 2025 Feb 5;25(1):176. doi: 10.1186/s12879-024-10379-z.
6
Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.评估在中国实施婴儿 13 价肺炎球菌结合疫苗国家免疫规划的成本效益。
PLoS One. 2018 Jul 25;13(7):e0201245. doi: 10.1371/journal.pone.0201245. eCollection 2018.
7
Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.患有基础疾病者侵袭性肺炎球菌病和肺炎的发病率及费用
BMC Health Serv Res. 2016 May 13;16:182. doi: 10.1186/s12913-016-1432-4.
8
Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019.1998 - 2019年美国48个月及以下儿童肺炎球菌疾病的发病率
Vaccine. 2024 Apr 19;42(11):2758-2769. doi: 10.1016/j.vaccine.2024.03.013. Epub 2024 Mar 13.
9
Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines.24价和31价肺炎球菌结合疫苗候选产品中新型血清型所致的健康经济负担。
Vaccine. 2024 Dec 2;42(26):126310. doi: 10.1016/j.vaccine.2024.126310. Epub 2024 Sep 10.
10
Economic burden of pneumococcal infections in children under 5 years of age.5 岁以下儿童肺炎链球菌感染的经济负担。
Hum Vaccin Immunother. 2018 Jan 2;14(1):106-110. doi: 10.1080/21645515.2017.1371378. Epub 2017 Nov 7.